RSS   Newsletter   Contact   Advertise with us
Post Online Media

Ultragenyx Pharmaceutical appoints Deborah Dunsire to board

UltragenyxUltragenyx Pharmaceutical, a biopharmaceutical company, announced the appointment of Deborah Dunsire to the company’s board of directors as an independent director.
Article continues below

READ MORE Ultragenyx appoints SVP and chief technical operations officer

Dr. Dunsire brings more than 25 years of management experience in the biopharmaceutical industry.

Prior to joining XTuit in 2017, Dr. Dunsire was president and chief executive officer of FORUM Pharmaceuticals.

From 2005 to 2008, she served as president and chief executive officer of Millennium Pharmaceuticals, Inc.

The company was acquired by Takeda Pharmaceutical Company Limited in 2008, and Dr. Dunsire served as president, CEO and a board member of Millennium: The Takeda Oncology Company until 2013.

Before joining Millennium Pharmaceuticals, Dr. Dunsire led the Novartis U.S. Oncology Business for more than ten years.

She also served on the board of Allergan, Inc. from 2006 to 2015.

Dr. Dunsire has received awards including the 2013 Boston CEO Conference Lifetime Achievement award, the 2011 MassBIO Innovative Leadership Award, the 2009 Healthcare Businesswomen’s Association’s Woman of the Year award, and the 2001 American Cancer Society Excalibur Award.

Dr. Dunsire is a graduate of the medical school of the University of the Witwatersrand, South Africa.



We use cookies to ensure that we give you the best experience on our website. Please allow cookies for fully-functioning website.

Allow Cookies Privacy Policy